Eagle's Eye View: Your Weekly CV Update From ACC.org Outcomes of Pre-ablation Transesophageal Echocardiograms; TAVI vs. SAVR in Women With Severe AS; Effects in the Use of Oral Anti-coagulants (OACs)
6 snips
Apr 16, 2025 Discover how pre-ablation transesophageal echocardiograms influence patient outcomes. Delve into groundbreaking research comparing TAVI and SAVR in women with severe aortic stenosis, revealing TAVI's potential superiority. Uncover insights from the OCEANIC-AF study, which sheds light on the differing effects of oral anti-coagulants on patient outcomes. These pivotal findings could reshape future cardiovascular treatment approaches.
AI Snips
Chapters
Transcript
Episode notes
Decline and Risk of Pre-Ablation TEE
- Pre-ablation transesophageal echocardiograms (TEE) use declined from 60% to under 50% between 2016 and 2020.
- Patients without anticoagulation and no pre-procedural TEE had a 30% higher risk of TIA.
TAVI Superior to SAVR in Women
- TAVI proved superior to SAVR at one year in women with severe aortic stenosis with fewer deaths, strokes, and rehospitalizations.
- The one-year composite event rate was 8.9% for TAVI vs 15.6% for SAVR, indicating better outcomes with TAVI.
Factor 11a Inhibitor Less Effective
- The novel factor 11a inhibitor Asundexian was less effective than Apixaban in preventing stroke or systemic embolism in AFib patients.
- Bleeding rates were similar, but overall, Asundexian did not match Apixaban's efficacy, leading to early trial termination.